Washington — The U.S. Food and Drug Administration has approved a new drug, rufinamide — marketed as Banzel — to treat severe epilepsy.
The drug is to be used as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome.
“This approval offers another treatment option for patients who suffer from these debilitating, severe seizures,” Dr. Russell Katz of the FDA’s Center for Drug Evaluation and Research said Thursday in a statement.
